Delving into the Latest Updates on Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes(Hershey Medical Center) with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Refractory Hodgkin Lymphoma

Originator Organization

Hershey Medical Center

Active Organization-

Inactive Organization

Hershey Medical Center

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus may be effective treatment for Hodgkin's lymphoma.
PURPOSE: Phase I trial to study the effectiveness of allogeneic Epstein-Barr virus-specific cytotoxic T cells in treating patients who have progressive, relapsed, or refractory Hodgkin's lymphoma.

Start Date01 Apr 2000

Sponsor / Collaborator

Hershey Medical Center

[+1]

100 Clinical Results associated with Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes(Hershey Medical Center)

Login to view more data

100 Translational Medicine associated with Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes(Hershey Medical Center)

Login to view more data

100 Patents (Medical) associated with Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes(Hershey Medical Center)

Login to view more data

100 Deals associated with Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes(Hershey Medical Center)

Login to view more data